eGVHD vs HemeOncBuddy
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
eGVHD
This educational tool assists healthcare professionals in assessing and scoring the severity of graft versus host disease (GVHD) in allogeneic stem cell transplantation recipients. It uses an algorithm-driven approach to apply internationally recognized criteria, providing differential information and automatic summaries to aid diagnosis.
- Algorithm-driven assessment
- GVHD severity scoring
- Differential information display
- Automatic summary generation
- Educational tool for clinicians
Read full descriptionHide full description
The “eGVHD App” is developed by the UZ Leuven (Belgium) in collaboration with the EBMT (European Bone Marrow Transplantation Society) Transplantation Complications Working Party and the National Institute of Health (Bethesda, USA). It is an electronic tool designed as an algorithm-driven application, to help clinicians apply the internationally recognized criteria for the assessment of graft versus host disease (GVHD), a pleiotropic disease affecting allogeneic stem cell transplantation recipients when their transplanted stem cells react against their own body. This app is not a medical tool aiming at replacing the diagnosis of a clinician, but a user-friendly educational tool. It helps health care professionals improve their ability to diagnose and score the severity of GVHD by showing the user differential information and it making an automatic summary of what has been filled in.
HemeOncBuddy
This app provides quick access to practice-changing clinical trials in Hematology and Oncology. It offers simplified summaries of trial background, inclusion/exclusion criteria, primary endpoints, and outcomes for easy reference.
- Practice-changing clinical trial summaries
- Hematology and Oncology focus
- Simplified trial information
- Inclusion and exclusion criteria
- Primary endpoints and outcomes
- Quick reference tool
Read full descriptionHide full description
HemeOncBuddy is a free study hub built for hematology and oncology fellows and trainees - everything you need to keep up with the literature and prep for boards, in one fast, searchable app. WHAT'S INSIDE - 1,500+ pivotal clinical-trial summaries, each in the same structure (background, inclusion criteria, arms, primary/secondary endpoints, median follow-up, key results, notable toxicities) so you can scan them quickly. - A Question Bank with board-style questions, tutor and timed modes, explanations, and progress tracking. - ~2,000 active-recall flashcards across oncology, malignant and benign heme, and pharmacology — plus visual staging decks. - 120+ concise disease-site board-prep notes. - A conference & abstract-deadline tracker so you never miss a submission window. MADE FOR STUDYING - Full dark mode and adjustable text size. - Optional free account (Sign in with Apple, Google, or email) to sync your saved trials, Qbank progress, and notes across iPhone, iPad, and Mac. - No ads. No paywall. No login required to browse. HemeOncBuddy is an educational study aid only. It is not a substitute for medical advice, clinical judgment, or current guidelines, and must not be used to diagnose or treat patients. Always verify against primary literature and current guidelines.
Screenshots
Verdict
The clearest difference is ratings volume: HemeOncBuddy at 18 against eGVHD's 2. eGVHD's advantage is iOS requirement (9.0 vs 15.0). On price, rating, update cadence and ads there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
On the App Store both sit at effectively the same score — 5.0 for eGVHD against 5.0 for HemeOncBuddy. That said, the two scores are not equally well evidenced: HemeOncBuddy has 18 ratings behind it against 2, so its average is the more settled of the two.
eGVHD ships an update every 16 months, HemeOncBuddy every 24 months. The most recent releases landed on September 16, 2026 and October 24, 2026 respectively.
| Parameter | eGVHD | HemeOncBuddy |
|---|---|---|
| Price | Free | Free |
| Rating | 5.0 (2 ratings) | 5.0 (18 ratings) |
| Positive reviews | — | 100.0% of reviews |
| Number of ratings | 2 | 18 — better |
| Update frequency | Every 16 months — better | Every 24 months |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 9.0 — better | 15.0 |
| Further details — not scored | ||
| Size | 81 MB | 16 MB |
| Age rating | 17+ | 17+ |
| Developer | nexuzhealth NV | Veli Bakalov |
Customer experience
eGVHD
HemeOncBuddy
In-app purchases
eGVHD
No in-app purchases
HemeOncBuddy
No in-app purchases
Questions
Is eGVHD free?
Is HemeOncBuddy free?
Which has better reviews, eGVHD or HemeOncBuddy?
Do eGVHD or HemeOncBuddy have ads?
Which is updated more often, eGVHD or HemeOncBuddy?
Other comparisons















